1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.

NeoGenomics Has Attractive Charts and Should Continue Its Uptrend

NeoGenomics Has Attractive Charts and Should Continue Its Uptrend

Let's see what the charts suggest.

Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

Lilly acquired the drug as part of its $8 billion acquisition of Loxo Oncology.

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Let's check out the charts to get a sense of where prices could be headed.

Purdue Pharma, DoJ in Talks to Resolve Federal Probes, Report Says

Purdue Pharma, DoJ in Talks to Resolve Federal Probes, Report Says

Purdue, owned by the Sackler family, is already deep in negotiations with officials across the country to resolve thousands of lawsuits alleging the pharma giant helped fuel the opioid addiction crisis.

Mallinckrodt Shares Jump as Pharma Giant Settles Ohio Opioid Lawsuits

Mallinckrodt Shares Jump as Pharma Giant Settles Ohio Opioid Lawsuits

In its pending settlement agreement with Cuyahoga and Summit counties, Mallinckrodt has agreed to pay $24 million cash and $6 million in generic products, including products for addiction treatment.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Cloudera's CEO Discusses Carl Icahn's Stake, R&D Efforts and More

Cloudera's CEO Discusses Carl Icahn's Stake, R&D Efforts and More

During a talk with TheStreet, Cloudera interim CEO Marty Cole argued that his company's merger with rival Hortonworks gives it the resources to develop an end-to-end platform that neither company could have built on its own.

The Charts of CVS Health Are Coming Out of Rehab

The Charts of CVS Health Are Coming Out of Rehab

Let's check out the charts.

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.